206 related articles for article (PubMed ID: 8280704)
1. Report on the Keystone symposium: cellular immunity and the immunotherapy of cancer II.
Lotze MT; Finn OJ
J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):79-87. PubMed ID: 8280704
[No Abstract] [Full Text] [Related]
2. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview.
Shinitzky M; Skornick Y
Prog Clin Biol Res; 1990; 348():95-125. PubMed ID: 2201036
[No Abstract] [Full Text] [Related]
3. [Immunology and cancer].
Brunner KT
Schweiz Med Wochenschr; 1973 Sep; 103(36):1249-52. PubMed ID: 4584090
[No Abstract] [Full Text] [Related]
4. Anti-idiotypic tumor vaccines.
Hellström KE; Hellström I
Int Rev Immunol; 1989; 4(4):337-46. PubMed ID: 2519931
[No Abstract] [Full Text] [Related]
5. Regulation of the immune response to antigens on the malignant cell surface.
Drebin JA; Perry LL; Carter R; Greene MI
Springer Semin Immunopathol; 1982; 5(2):175-92. PubMed ID: 6293112
[No Abstract] [Full Text] [Related]
6. The functions of the macrophage in malignant disease.
Alexander P
Annu Rev Med; 1976; 27():207-24. PubMed ID: 779596
[No Abstract] [Full Text] [Related]
7. [Cancer and the lymphatic system].
Grekh IF
Vopr Onkol; 1971 Sep; 17(10):101-10. PubMed ID: 4947716
[No Abstract] [Full Text] [Related]
8. Clinical aspects of cancer immunity.
Moore GE
Prog Clin Cancer; 1973; 5():107-20. PubMed ID: 4571116
[No Abstract] [Full Text] [Related]
9. The gordian knot of tumour immunology.
Amlot P
Guys Hosp Rep; 1974; 123(1):43-51. PubMed ID: 4549511
[No Abstract] [Full Text] [Related]
10. [Interleukin-2 and cancer immunotherapy].
Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
[No Abstract] [Full Text] [Related]
11. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes.
Fenton RG; Longo DL
J Natl Cancer Inst; 1997 Feb; 89(4):272-5. PubMed ID: 9048827
[No Abstract] [Full Text] [Related]
12. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
13. Bacillus Calmette-Guerin in the treatment of neoplastic disease.
Laucius JF; Bodurtha AJ; Mastrangelo MJ; Creech RH
J Reticuloendothel Soc; 1974 Dec; 16(6):347-73. PubMed ID: 4616079
[No Abstract] [Full Text] [Related]
14. Tumor immunology.
Stevenson HC; Tsang KY
Immunol Ser; 1990; 50():513-33. PubMed ID: 2091767
[No Abstract] [Full Text] [Related]
15. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
[No Abstract] [Full Text] [Related]
16. Tumour immunology.
Heslop BF
Aust N Z J Surg; 1977 Oct; 47(5):688-93. PubMed ID: 305776
[TBL] [Abstract][Full Text] [Related]
17. BCG in cancer therapy: theoretical bases of immunotherapy.
Dodd MJ
Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
[No Abstract] [Full Text] [Related]
18. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
19. [Immunity and immunosuppression in tumor growth].
Govallo VI
Vopr Onkol; 1987; 33(4):91-9. PubMed ID: 3296437
[No Abstract] [Full Text] [Related]
20. Immunotherapy of cancer.
Oettgen HF
N Engl J Med; 1977 Sep; 297(9):484-91. PubMed ID: 301988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
